Connor, Clark & Lunn Investment Management (CC&L)’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-49,553
Closed -$17.4M 1630
2026
Q1
$17.4M Buy
+49,553
New +$17.7M 0.04% 342
2025
Q4
Sell
-7,335
Closed -$2.07M 1525
2025
Q3
$2.07M Buy
7,335
+1,135
+18% +$329K 0.01% 845
2025
Q2
$1.73M Sell
6,200
-55,512
-90% -$15.7M 0.01% 903
2025
Q1
$19.2M Buy
61,712
+7,536
+14% +$2.23M 0.08% 202
2024
Q4
$14.1M Buy
54,176
+25,541
+89% +$7.58M 0.06% 239
2024
Q3
$9.23M Sell
28,635
-29,127
-50% -$9.53M 0.04% 297
2024
Q2
$18M Buy
57,762
+14,860
+35% +$4.37M 0.08% 195
2024
Q1
$12.2M Sell
42,902
-9,546
-18% -$2.79M 0.05% 274
2023
Q4
$15.1M Buy
52,448
+51,384
+4,829% +$14M 0.07% 220
2023
Q3
$286K Sell
1,064
-156,809
-99% -$39.1M ﹤0.01% 1156
2023
Q2
$35.1M Sell
157,873
-75,944
-32% -$17.6M 0.18% 98
2023
Q1
$56.5M Buy
233,817
+149,770
+178% +$36.8M 0.31% 67
2022
Q4
$22.1M Buy
84,047
+69,149
+464% +$18.5M 0.13% 126
2022
Q3
$3.36M Sell
14,898
-76,674
-84% -$18.6M 0.02% 396
2022
Q2
$22.3M Sell
91,572
-163,787
-64% -$40.1M 0.14% 117
2022
Q1
$61.8M Buy
255,359
+189,078
+285% +$43.4M 0.3% 58
2021
Q4
$14.9M Buy
66,281
+40,898
+161% +$8.63M 0.07% 194
2021
Q3
$5.4M Sell
25,383
-6,049
-19% -$1.39M 0.03% 321
2021
Q2
$7.66M Sell
31,432
-43,131
-58% -$10.6M 0.04% 274
2021
Q1
$18.6M Buy
74,563
+16,292
+28% +$3.89M 0.1% 161
2020
Q4
$13.4M Sell
58,271
-7,787
-12% -$1.8M 0.08% 193
2020
Q3
$16.8M Buy
66,058
+38,071
+136% +$9.43M 0.11% 151
2020
Q2
$6.6M Buy
27,987
+3,717
+15% +$848K 0.05% 255
2020
Q1
$4.92M Sell
24,270
-10,139
-29% -$2.21M 0.04% 251
2019
Q4
$8.29M Sell
34,409
-2,975
-8% -$656K 0.06% 201
2019
Q3
$7.23M Sell
37,384
-24,675
-40% -$4.74M 0.05% 213
2019
Q2
$11.4M Buy
62,059
+32,075
+107% +$5.74M 0.07% 175
2019
Q1
$5.7M Sell
29,984
-141
-0.5% -$26.9K 0.04% 262
2018
Q4
$5.86M Sell
30,125
-220,575
-88% -$43M 0.04% 243
2018
Q3
$52M Buy
250,700
+115,350
+85% +$22.7M 0.29% 64
2018
Q2
$25M Buy
135,350
+3,925
+3% +$694K 0.14% 113
2018
Q1
$22.4M Sell
131,425
-15,375
-10% -$2.82M 0.14% 127
2017
Q4
$25.5M Sell
146,800
-3,950
-3% -$699K 0.15% 122
2017
Q3
$28.1M Sell
150,750
-38,475
-20% -$6.82M 0.17% 100
2017
Q2
$32.6M Buy
189,225
+155,525
+461% +$25.3M 0.21% 84
2017
Q1
$5.53M Sell
33,700
-52,350
-61% -$8.7M 0.04% 236
2016
Q4
$12.6M Buy
86,050
+52,650
+158% +$7.92M 0.09% 148
2016
Q3
$5.57M Sell
33,400
-93,175
-74% -$15.8M 0.04% 234
2016
Q2
$19.3M Sell
126,575
-84,225
-40% -$13.1M 0.14% 119
2016
Q1
$31.6M Sell
210,800
-51,975
-20% -$7.72M 0.24% 67
2015
Q4
$42.7M Sell
262,775
-81,425
-24% -$12.8M 0.36% 51
2015
Q3
$47.6M Buy
344,200
+294,550
+593% +$46.4M 0.39% 46
2015
Q2
$7.62M Buy
+49,650
New +$7.95M 0.07% 124
2014
Q4
Sell
-67,900
Closed -$9.54M 576
2014
Q3
$9.54M Sell
67,900
-62,300
-48% -$8.13M 0.08% 103
2014
Q2
$16.4M Buy
+130,200
New +$15.1M 0.12% 95
2014
Q1
Sell
-117,921
Closed -$14.3M 675
2013
Q4
$14.3M Buy
117,921
+97,866
+488% +$11.1M 0.11% 81
2013
Q3
$2.31M Sell
20,055
-41,550
-67% -$4.51M 0.02% 181
2013
Q2
$6.41M Buy
+61,605
New +$6.39M 0.06% 92

Other funds holding AMGN

Connor, Clark & Lunn Investment Management (CC&L)'s AMGN Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Amgen (AMGN) in Q2 2026, closing a stake of 49,553 shares — an estimated $17.4M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AMGN in Q2 2013 and held it in 48 quarters. The position peaked at $61.8M in Q1 2022. 3,139 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Amgen position as of Q2 2026 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 49,553 Amgen shares in Q2 2026, an estimated $17.4M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Amgen in Q2 2013 and held it in 48 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Amgen position peaked at $61.8M in Q1 2022.
  • 3,139 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.